Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin Lymphoma

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Rehan, Fareed Ahmed ^a   Bohlius, J ^b   Brillant, C ^b   Knauel, I ^b   Specht, L ^b   Engert, A ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHI SQUARE TEST; CLINICAL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; DATA EXTRACTION; HODGKIN DISEASE; HUMAN; INTERVENTION STUDY; OUTCOME ASSESSMENT; PUBLICATION; QUALITY CONTROL; REVIEW; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

EID: 44949117035     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007110     Document Type: Review

References (45)

1. Altman 2001 Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al.The revised CONSORT statement for reporting randomized trials: explanation and elaboration. [see comment]. [Review] [204 refs]. Annals of Internal Medicine 2001;134(8):663-94.
2. Carbone 1971 Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Research 1971;31(11):1860-61.
3. Carde 1993 Carde P, Hagenbeek A, Hayat M, Monconduit M, Thomas J, Burgers MJ, et al.Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2258-72.
4. Carde 2005 Carde P. The chemotherapy/radiation balance in advanced Hodgkin's lymphoma: overweight which side? [see comment] [comment]. Journal of Clinical Oncology 2005;23(36):9058-62.
5. Connors 2001 Connors JM, Noordijk EM, Horning SJ. Hodgkin's lymphoma: basing the treatment on the evidence. [Review] [95 refs]. Hematology 2001:178-93.
6. Connors 2005 Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. [Review] [72 refs]. Journal of Clinical Oncology 2005;23(26):6400-8.
7. DeVita 1997 DeVita VT Jr, Mauch PM, Harris NL. Hodgkin's disease. In: De-VitaVTJr, HellmannS, RosenbergSA editor(s). Cancer: principles and pratice of oncology. 5th Edition. Philadelphia: Lippincott-Raven, 1997:2242-83.
8. Dickersin 1993 Dickersin K, Min YI. NIH clinical trials and publication bias. Online Journal of Current Clinical Trials 1993;50:4967.
9. Diehl 2004 Diehl V. Chemotherapy or combined modality treatment: the optimal treatment for Hodgkin's disease. [comment]. Journal of Clinical Oncology 2004;22(1):15-8.
10. Diehl 2005 Diehl V, Re D, Josting A. Hodgkin's disease: clinical manifestations, staging, and therapy. In: Hoffman, R editor(s). Hematology: basic principles and practice. 4th Edition. Elsevier, 2005:1347-78.
11. Egger 1997 Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. [see comment]. Lancet 1997;350(9074):326-9.
12. Egger M 1997 Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997;315(7121):1533-7.
13. Engert 2007 Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, et al.Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. Journal of Clinical Oncology 2007;25(23):3495-3502.
14. FDA 2007 U.S. Department of Health and Human Services Food and Drug Administration - Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Department of Health and Human Services Food and Drug Administration 2007; http://www.fda.gov/cder/guidance/index.htm May, 2007:4-9.
15. Franklin 2005 Franklin JG, Paus MD, Pluetschow A, Specht L. Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. [Review] [127 refs]. Cochrane Database of Systematic Reviews 2005, Issue 4.
16. Fuchs 2006 Fuchs M, Diehl V, Re D. Current strategies and new approaches in the treatment of Hodgkin's lymphoma. [Review] [117 refs]. Pathobiology 2006;73(3):126-40.
17. Hagenbeek 2000 Hagenbeek A, Eghbali H, Freme C, Meerwaldt JH, Divine M, Raemaekers JM, et al.Three cycles of MOPP/ABV(M/A) hybrid and involved-field irradiation is more effective than subtotal nodal irradiation (STNI) in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's disease (HD): preliminary results of the EORTC-GELA H8-F randomized trial in 543 patients. Blood 2000;96(11):575a.
18. Higgins 2002 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
19. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. [Review] [24 refs]. British Medical Journal 2003;327(7414):557-60.
20. Higgins 2006 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library. Chichester, UK: John Wiley & Sons Ltd, September, 2006.
21. Juni 2002 Juni P, Holenstein F, Sterne J, Bartlett C, Egger M. Direction and impact of language bias in meta-analyses of controlled trials: empirical study. [see comment]. International Journal of Epidemiology 2002;31(1):115-23.
22. Klimm 2005 Klimm B, Engert A, Diehl V. First-line treatment of Hodgkin's lymphoma. [Review] [50 refs]. Current Hematology Reports 2005;4(1):15-22.
23. Lister 1989 Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al.Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. [see comment] [erratum appears in J Clin Oncol 1990 Sep;8(9):1602]. Journal of Clinical Oncology 1989;7(11):1630-6.
24. Loeffler 1998 Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, et al.Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. [see comment]. Journal of Clinical Oncology 1998;16(3):818-29.
25. Mauch 1988 Mauch P, Tarbell N, Weinstein H, Silver B, Goffman T, Osteen R, et al.Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. Journal of Clinical Oncology 1988;6(10): 1576-83.
26. Mauch 1999 Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM. Hodgkin's disease. 1st Edition. Philadelphia: Lippicott Williams & Wilkins, 1999.
27. Mauch 2005 Mauch P, Ng A, Aleman B, Carde P, Conszine L, Diehl V, et al.Report from the Rockefeller Foundation sponsored International workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease. European Journal of Heamatology 2005;75(Suppl 66):68-76.
28. Meyer 2005 Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, et al.Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. [see comment]. Journal of Clinical Oncology 2005;23(21):4634-42.
29. Meyer RM 2005 Meyer RM. Is there convincing evidence for the use of chemotherapy alone in patients with limited stage Hodgkin's lymphoma?. [Review] [34 refs]. European Journal of Haematology 2005; Supplementum. (66):115-20.
30. Moher 1995 Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Controlled Clinical Trials 1995;16(1):62-73.
31. Moher 1999 Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. [see comment]. [Review] [49 refs]. Lancet 1999;354(9193):1896-1900.
32. Moher 2005 Moher D, Schulz KF, Altman D, CONSORT Group. The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials 2001. Explore-The Journal of Science & Healing 2005;1(1):40-5.
33. Mueller 1999 Mueller NE, Gruffermann S. The epidemiology of Hodgkin's disease. In: MauchPM, ArmitageJO, Diehl, V, HoppeRT, WeissLM editor (s). Hodgkin's disease. 1st Edition. Philadelphia: Lippicott Williams & Wilkins, 1999:61-78.
34. Ng 2002 Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, et al.Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. Journal of Clinical Oncology 2002;20(8):2101-8.
35. Oxman 1992 Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. [see comment]. Annals of Internal Medicine 1992;116(1): 78-84.
36. Parmar 1998 Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. [erratum appears in Stat Med. 2004 Jun 15;23(11):1817]. Statistics in Medicine 1998;17(24):2815-34.
37. Press 2001 Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, et al.Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. Journal of Clinical Oncology 2001;19(22):4238-44.
38. Sasse 2006 Sasse S, Diehl V, Engert A. Combined modality treatment for early-stage Hodgkin's lymphoma: the GHSG experience. Haematologica Reports 2006;2(7):19-22.
39. Sieber 2002 Sieber M, Franklin J, Tesch H, Rueffer U, Brillant C, Reineke T, et al.Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin's disease: results of the German Hodgkin's Lymphoma Study Group (GHSG) trial HD7. Blood 2002;100(11 (Pt 2)):93a.
40. Specht 1998 Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. Journal of Clinical Oncology 1998;16(3):830-43.
41. Swerdlow 2003 Swerdlow AJ. Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma. [Review] [99 refs]. European Journal of Nuclear Medicine & Molecular Imaging 2003;30 Suppl 1:S3-12.
42. Thomas 2002 Thomas RK, Re D, Zander T, Wolf J, Diehl V. Epidemiology and etiology of Hodgkin's lymphoma. [Review] [75 refs]. Annals of Oncology 2002;13 Suppl 4:147-52.
43. Tierney 2007 Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8(16):1745-1762.
44. Tubiana 1989 Tubiana M, Henry-Amar M, Carde P, Burgers JM, Hayat M, Van der SE, et al.Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 1989;73(1):47-56.
45. Yusuf 1991 Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266(1):93-8.